Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 10Gynecologic 1Breast 1

Conditions

Breast Neoplasms 40Triple Negative Breast Neoplasms 34Neoplasm Metastasis 5Brain Neoplasms 3Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Advanced Breast Cancer 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Locally Advanced Non-resectable Breast Cancer 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm, Residual 1Meningeal Carcinomatosis 1HER2-negative Breast Cancer 1Glioblastoma 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Cancer Metastatic 1

Interventions

pembrolizumab 18Nivolumab 12atezolizumab 5Ipilimumab 4Cyclophosphamide 4fludarabine 3Paclitaxel 3Magnetic Resonance Spectroscopy 3Fluorodeoxyglucose F18 3Docetaxel 3Carboplatin 3spartalizumab 2cabozantinib 2avelumab 2aldesleukin 2Specimen Handling 2Interleukin-2 2Immunoglobulin G 2zanidatamab 1veliparib 1trastuzumab deruxtecan 1tislelizumab 1temsirolimus 1sargramostim 1sacituzumab govitecan 1rucaparib 1regorafenib 1poly ICLC 1pemigatinib 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × sacituzumab govitecan × Breast × Clear all
NCT03992131 2024-01-16

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

pharmaand GmbH

Phase 1/2 Terminated
25 enrolled 11 charts
BreastGenitourinaryGynecologic

Carcinoma, Transitional Cell, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡